NVO

NYSE:NVO

Novo Nordisk A/S

Add to Watchlist
  • Stock

65.60

−1.28%

14.65

USD last updated 15/08 02:20:07

Last Close

50.95

14/08 22:31

Market Cap

628.74B

Beta: 0.31

Volume Today

16.42M

Avg: 1.35M

PE Ratio

43.81

PFCF: 52.23

Dividend Yield

0.25%

Payout:37.96%

Novo Nordisk A/S, a Danish global healthcare company, is advancing its oral semaglutide drug Rybelsus for diabetes, with HSBC projecting peak sales of over DKK15 billion ($2.34 billion) after 2034. The bank maintained a 'Hold' rating on the stock due to concerns about market size and prescription overhang, but noted potential upside if Wegovy prescriptions in the U.S. recover. The company's portfolio includes GLP-1 therapies like Ozempic and Wegovy, as well as insulin and growth hormone treatments.

insidermonkey.com

Zacks Research Daily highlights recent performance and outlook for several major stocks, including Broadcom, Philip Morris, and Novo Nordisk. Broadcom is showing strong growth driven by AI semiconductors and VMware integration, with expected AI revenues of $5.1 billion in Q3 2025, though gross margins may decline due to product mix and high debt. Philip Morris benefits from strong smoke-free product demand, particularly IQOS and ZYN, with net revenues up 7.1% year-over-year and adjusted EPS projected between $7.43 and $7.56, though it faces premium valuations and regulatory headwinds. Novo Nordisk underperformed due to lower Wegovy sales amid knockoff GLP-1 competition and patent expiry concerns, despite a Q2 earnings beat; the company is investing in production and reviewing oral and higher-dose formulations. Other companies like Sony, HCA Healthcare, and Cummins also receive analysis, with positive trends in specific segments offset by macro risks such as currency volatility and tariffs.

finance.yahoo.com

Eli Lilly has launched Mounjaro KwikPen, a single-use prefilled pen for once-weekly administration, in India to treat type 2 diabetes and obesity. The pen comes in six dose strengths with prices starting from Rs 14,000 for 2.5 mg to Rs 27,500 for 12.5 mg and 15 mg doses. The launch aims to enable personalized treatment plans for patients. Winselow Tucker, President and General Manager of Lilly India, emphasized the innovation's role in improving care quality. The medication is prescription-only and not approved for cosmetic weight loss. This launch intensifies competition with Novo Nordisk, which previously launched Mounjaro in lower dose vials in March.

m.economictimes.com

Eli Lilly has increased the list price of its weight loss and diabetes medication Mounjaro in the UK by 170% to £330 for the highest dose, aligning it with European market levels. The price hike is not directly tied to the US MFN order, though it coincides with international drug pricing discussions. The company maintains that the change ensures consistency with other European markets and offers savings programs to offset costs. The UK's NHS confirms continued availability of the drug for obesity and type 2 diabetes treatments. The previous UK list price was £122, and the new price remains significantly lower than the US list price of $1,079.77. The move comes amid broader debates over drug pricing, with President Trump's MFN executive order calling for lower drug prices in the US by matching international levels. Reports suggest some pharmaceutical companies may be adjusting prices abroad to offset potential reductions in the US, while also facing potential US tariffs on pharmaceutical goods. Patient reactions in the US include reduced dosages and financial strain due to rising costs and insurance restrictions.

pharmexec.com

Novo Nordisk, a Danish pharmaceutical company, has launched its weight-loss drug Wegovy in South Africa, marking its first entry into the African market. The drug, a once-weekly GLP-1 receptor agonist, is introduced to address the country's significant obesity crisis, where approximately 20 million adults are overweight and fewer than 1% receive treatment. The launch comes after a 30% drop in Novo Nordisk's share price due to a profit warning, though the company's strong performance in the U.S. market provides optimism. Wegovy will be available in five dose strengths, with pricing to be announced next week. It directly competes with Eli Lilly’s Mounjaro, which has a starting price of R3,400 for four vials and is currently limited to diabetes treatment. Novo Nordisk also plans to expand Wegovy’s availability to other African markets, including Egypt. The World Health Organization has endorsed weight-loss drugs as part of a broader shift in obesity treatment, though high costs may restrict access.

photonews.com.pk

    Description

    Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other ch...Show More

    Earnings

    Earnings per Share (Estimate*)

    0.20.40.60.812017-08-102019-08-092021-08-042023-08-102025-01-29

    Revenue (Estimate*)

    10B20B30B40B50B60B70B2017-08-102019-08-092021-08-042023-08-102025-01-29

    *Estimate based on analyst consensus